Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley BankPRNewsWire • 03/12/23
Nektar stock drops more than 30% after study involving lupus treatment will not go forwardMarket Watch • 02/23/23
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus ErythematosusPRNewsWire • 02/23/23
Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)Business Wire • 02/01/23
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CAPRNewsWire • 01/04/23
Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law FirmPRNewsWire • 12/15/22
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual MeetingPRNewsWire • 12/12/22
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual MeetingPRNewsWire • 11/10/22
Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell ImmunotherapyPRNewsWire • 11/09/22
Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/27/22
Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial MarketsPRNewsWire • 10/25/22
PureTech Health confirms ‘possible combination' with Nektar TherapeuticsProactive Investors • 10/07/22
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) CongressPRNewsWire • 09/07/22